Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
about
Prevention of chemotherapy-induced ovarian damage: possible roles for hormonal and non-hormonal attenuating agentsFemale reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications'An ounce of prevention is worth a pound of cure': the case for and against GnRH-agonist for fertility preservation.Late effects of blood and marrow transplantation.Clinical guide to fertility preservation in hematopoietic cell transplant recipientsMelatonin and Fertoprotective Adjuvants: Prevention against Premature Ovarian Failure during Chemotherapy.Fertility issues of breast cancer survivors.Fertility preservation and GnRHa for chemotherapy: debate.Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update.Gonadotropin-Releasing Hormone Analog Cotreatment for the Preservation of Ovarian Function during Gonadotoxic Chemotherapy for Breast Cancer: A Meta-Analysis.Gonadotropin-releasing hormone for preservation of ovarian function during chemotherapy in lymphoma patients of reproductive age: a summary based on 434 patientsGoserelin for ovarian protection during breast-cancer adjuvant chemotherapy.Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies.Utility of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a systematic review and meta-analysis.SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study.Fertility Preservation Methods in Breast Cancer.Chemotherapy-Induced Amenorrhea - An UpdateApplicability of adult techniques for ovarian preservation to childhood cancer patients.Protecting Effects of Gonadotropin-Releasing Hormone Agonist on Chemotherapy-Induced Ovarian Damage in Premenopausal Breast Cancer Patients: A Systematic Review and Meta-Analysis.Concurrent Gonadotropin-Releasing Hormone Agonist Administration with Chemotherapy Improves Neoadjuvant Chemotherapy Responses in Young Premenopausal Breast Cancer Patients.Fertility counseling of young breast cancer patients.Preserving Fertility in Children and Adolescents with Cancer.Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.Oncofertility in Canada: gonadal protection and fertility-sparing strategies.Sphingosine-1-phosphate prevents chemotherapy-induced human primordial follicle death.Fertility preservation options after gonadotoxic chemotherapyUtility of GnRH-agonists for Fertility Preservation in Women With Operable Breast Cancer: Is It Protective?Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain.Fertility outcome of breast cancer and Hodgkin's lymphoma female survivors: a growing clinical challenge for gynecologists and oncologists.Fertility issues in cancer survivorship.Management of acute myeloid leukemia during pregnancy.Preserving fertility when choosing chemotherapy regimens - the role of gonadotropin-releasing hormone agonists.Preservation of Fertility or Ovarian Function in Patients with Breast Cancer or Gynecologic and Internal Malignancies.Circulating microRNA-451 as a predictor of resistance to neoadjuvant chemotherapy in breast cancer.Impact of age on cytotoxic-induced ovarian failure in breast cancer treated with adjuvant chemotherapy and triptorelin.Factors associated with ovarian function recovery after chemotherapy for breast cancer: a systematic review and meta-analysis.Adjuvant hormonal therapy and fertility preservation in premenopausal breast cancer: a survey among Italian oncologists.Circulating Tumor Cells and Tumor Stem Cells Detection in the Peripheral Blood Mononuclear Cells of Breast Cancer.BRMS1 gene expression may be associated with clinico-pathological features of breast cancer.GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro.
P2860
Q28240178-D43073CA-B79C-42C9-A654-57156C1C70B9Q28383280-1A6D20BB-59A6-43D7-87D2-982DAA42FEAAQ30360464-9DDA86A9-5D75-48C2-8AA7-07B17150381BQ33574136-4C2C90AE-628D-4E37-86C8-54286B7FC080Q33809651-87784AF3-F1E9-47CD-A0E2-37842B430402Q33838766-6B133CC9-C88E-416B-8AAA-40C999437335Q33885680-53B44A66-1FB5-43AD-B075-97D2D4D0A7F1Q34090263-B10E23B2-10BC-429E-92DC-CA898DC18501Q34743455-D5119AF8-E07F-4835-B5F9-FB8A9FE3D769Q34785329-3060EA31-036E-45B6-B35D-23FB0E8DDDF0Q35060296-120E7889-5451-427F-B7FE-E481EC7CA74AQ35511100-ABD9FD00-9488-4A8A-B607-70FCD0807C76Q35766397-1620B723-F55F-44CC-8A98-D098FE136729Q35856600-E4A36AB2-075A-481D-874E-7DB6C682F661Q36032817-CCD6D602-B88A-48E4-A4EE-46B7225272FBQ36131370-DEF6485D-CFC3-46C3-9B2B-C99A7F75A27AQ36295133-71997BCB-FBC1-4EC4-AD15-0CFEECBC634BQ36295588-0BCEBC86-3074-4971-A0C5-EDAF92CBAF1FQ36404774-8CE4B665-2C52-4B92-BE93-F78C36DB2EBDQ36441539-D7BF0EF4-941C-4337-BE1B-A03B0CD9A4A1Q36963384-23A88890-F2A9-416B-8809-10AABAB03117Q37055811-02F77E5B-4E3C-4B3F-8880-958A50156A97Q37213101-3DE6CDC9-AB9C-4958-B57F-4F36030950DEQ37364626-89E55DEB-B1C8-443C-BE2C-B35EA14D3A0DQ37387475-41ED04C6-3D84-4F8D-94DD-54F659818DB7Q37463079-ECFA489B-EA41-4531-81AF-3A37EBA1F1A7Q37679148-893A0E66-189E-4797-BAC9-D4DD6FC4C8CCQ38109554-9B6C15B6-896F-4D76-8F2D-5B8747DD2D0CQ38113299-801774A0-3073-4ACE-9048-AB4A5C6F2D45Q38194105-1E515C14-EE40-4399-88AB-D7CF2853D578Q38232850-47CE2924-2CC1-4C9C-8A82-C7D5E42517A1Q38397291-1474C203-EDDD-4AB8-8AD5-7BC9B98B0687Q38606467-969785C1-784C-46CF-AAFB-65B71F6D3AB6Q38779495-5E46CA77-84FE-4407-B31E-CF2C279858FCQ38913042-A0BFA174-1CCD-4265-91D0-6211C93CDC7CQ38963455-5FAC4E07-82CF-4445-8841-33C02E632987Q39022556-26BC6010-F442-48FD-9200-CA2CFA86CD07Q39986271-BD099CA0-0B82-44F7-89D9-B189EDE9A844Q40202794-EEEE22F3-9052-48CD-BBF8-71E3F139E35DQ40432160-1E7F73AC-4ECB-4C36-AD0C-42206D16B2F0
P2860
Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Randomized trial using gonadot ...... hemotherapy for breast cancer.
@ast
Randomized trial using gonadot ...... hemotherapy for breast cancer.
@en
type
label
Randomized trial using gonadot ...... hemotherapy for breast cancer.
@ast
Randomized trial using gonadot ...... hemotherapy for breast cancer.
@en
prefLabel
Randomized trial using gonadot ...... hemotherapy for breast cancer.
@ast
Randomized trial using gonadot ...... hemotherapy for breast cancer.
@en
P2093
P2860
P356
P1476
Randomized trial using gonadot ...... hemotherapy for breast cancer.
@en
P2093
Amy P Moore
Charles E Cox
Margaret Gross-King
Mensura Lacevic
Pamela N Munster
Roohi Ismail-Khan
Susan E Minton
W Bradford Carter
P2860
P304
P356
10.1200/JCO.2011.34.6890
P407
P577
2012-01-09T00:00:00Z